Want to see PRLD full AI Analyst Report?
PRLD Stock Chart & Stats
$2.45
-$0.05(-4.55%)
At close: 4:00 PM EST
$2.45
-$0.05(-4.55%)
Day’s Range― - ―
52-Week Range$0.75 - $5.69
Previous CloseN/A
Volume107.75K
Average Volume (3M)256.05K
Market Cap
$334.51M
Enterprise Value$218.39
Total Cash (Recent Filing)$81.55M
Total Debt (Recent Filing)$17.72M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 19, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding64,917,175
10 Day Avg. Volume194,393
30 Day Avg. Volume256,051
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside246.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$28.45M
Bulls Say, Bears Say
Bulls Say
Clinical-stage Pipeline ProgressAdvancing PRT12396 into a Phase 1 trial after regulatory clearance materially de-risks that program versus preclinical assets. Clinical entry creates discrete value inflection points, demonstrates regulatory and operational execution, and increases likelihood of partnerships or milestone revenues over the next 2–6 months.
Differentiated Preclinical DataFirst-in-class KAT6A degrader data showing complete regressions, better pathway disruption than dual inhibitors, and synergy with standard therapies suggest meaningful scientific differentiation. That improves the program's partnerability and the probability of clinical success, supporting durable strategic optionality.
Extended Cash RunwayProceeds from the ~ $90M offering plus existing cash increase runway into Q2 2028, materially reducing near-term financing pressure. This funding horizon allows the company to advance multiple clinical and preclinical programs, execute IND filings, and hit clinical milestones without immediate dilution risk.
Bears Say
Ongoing Negative Cash FlowSustained negative operating and free cash flow, even with improvement, means the company cannot self-fund development. Persistent cash burn requires recurring access to capital markets or partners and compresses financial flexibility, raising the odds of dilution or slowed program pace if funding conditions deteriorate.
Deep Cumulative Losses & Equity ErosionLarge, multi-year operating losses have materially eroded shareholders' equity, undermining balance sheet resilience. Negative returns and shrinking equity reduce borrowing capacity and raise the sensitivity of the business to clinical setbacks, potentially forcing unfavorable financing terms if progress stalls.
No Product Revenue; Funding RelianceAs a clinical-stage biotech without marketed products, Prelude lacks recurring revenue and depends on collaborations, milestone payments, and capital raises. This business model is inherently binary and funding-sensitive: clinical failures or slower readouts can quickly impair the company's ability to sustain R&D spend and strategic initiatives.
Prelude Therapeutics News
PRLD FAQ
What was Prelude Therapeutics’s price range in the past 12 months?
Prelude Therapeutics lowest stock price was $0.75 and its highest was $5.69 in the past 12 months.
What is Prelude Therapeutics’s market cap?
Prelude Therapeutics’s market cap is $334.51M.
When is Prelude Therapeutics’s upcoming earnings report date?
Prelude Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.
How were Prelude Therapeutics’s earnings last quarter?
Prelude Therapeutics released its earnings results on May 12, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.122.
Is Prelude Therapeutics overvalued?
According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued.
Does Prelude Therapeutics pay dividends?
Prelude Therapeutics does not currently pay dividends.
What is Prelude Therapeutics’s EPS estimate?
Prelude Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Prelude Therapeutics have?
Prelude Therapeutics has 64,917,175 shares outstanding.
What happened to Prelude Therapeutics’s price movement after its last earnings report?
Prelude Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Prelude Therapeutics?
Currently, no hedge funds are holding shares in PRLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prelude Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (246.94% Upside)
$8.50 (246.94% Upside)
Hedge Fund Trend
Increased
By 11.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 13.2%
Last 30 Days ▲ 13.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.30%
Trailing 12-Months
Company Description
Prelude Therapeutics
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
PRLD Stock 12 Month Forecast
Average Price Target
$8.50
▲(246.94% Upside)
Technical Analysis
Ownership Overview
36.92% Insiders
2.39% Mutual Funds
37.60% Other Institutional Investors
18.05% Public Companies and
Individual Investors